ANI Pharmaceuticals CEO Sells $4.27M in Open Market Transaction
ANIP sits 43% above its 52-week low of $56.71.
Summary
ANI Pharmaceuticals' President and CEO, Nikhil Lalwani, sold 55,000 shares for $4.27 million in an open market transaction, following a previously filed Form 144.
Key Events · Ownership and Investor Activity · ANIP
-
CEO Sells Shares
Nikhil Lalwani, President and CEO, sold 55,000 shares of common stock in an open market transaction on May 11, 2026.
-
Total Transaction Value
The sale generated proceeds of $4,266,350.00 at a weighted average price of $77.57 per share.
-
Follows Form 144 Filing
This Form 4 reports the execution of the sale previously indicated by a Form 144 filed on May 11, 2026, for the same number of shares.
-
Significant Transaction Size
The sale value represents 0.232% of the company's current market capitalization, indicating a material disposition by a key insider.
Analysis · ANIP · Life Sciences
Nikhil Lalwani, the President and CEO of ANI Pharmaceuticals, executed an open market sale of 55,000 shares totaling $4.27 million. This transaction follows a Form 144 filing on May 11, 2026, which indicated an intent to sell these shares. While the company recently reported strong financial results and FDA approval, a significant sale by the CEO can be interpreted as a lack of conviction or a move to diversify holdings, potentially offsetting some of the positive sentiment from recent corporate news. The sale represents a notable portion of the company's market capitalization, making it a material event for investors.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANIP was trading at $80.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $56.71 to $99.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.